Pediatrix Medical Group (MD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this physician group would post earnings of $0.37 per share when it actually produced earnings of $0.51, delivering a surprise of 37.84%.Over the last four quarters, t ...

Financial Performance - Net revenue for the three months ended March 31, 2025, was $458.4 million, a decrease of $36.7 million, or 7.4%, compared to $495.1 million for the same period in 2024[73] - Same-unit net revenue increased by $26.1 million, or 6.2%, driven by a $19.4 million increase from net reimbursement-related factors and a $6.7 million increase related to patient service volumes[73] - Adjusted EBITDA for the three months ended March 31, 2025, was $49.2 million, compared to $37.2 million for the same period in 2024, reflecting an increase of $11.9 million[72] - Adjusted EPS for the three months ended March 31, 2025, was $0.33, compared to $0.20 for the same period in 2024, representing a 65% increase[72] - Income from operations increased by $16.2 million, or 102.0%, to $32.1 million for the three months ended March 31, 2025, compared to $15.9 million for the same period in 2024[79] - Operating margin improved to 8.4% for the three months ended March 31, 2025, up from 4.9% for the same period in 2024[80] - Net income rose to $20.7 million for the three months ended March 31, 2025, compared to $4.0 million for the same period in 2024[83] - Adjusted EBITDA increased to $49.2 million for the three months ended March 31, 2025, from $37.2 million for the same period in 2024[83] Expenses - Practice salaries and benefits decreased by $32.1 million, or 8.7%, to $337.0 million for the three months ended March 31, 2025, compared to $369.1 million for the same period in 2024[74] - General and administrative expenses were $58.6 million for the three months ended March 31, 2025, a decrease of $1.6 million compared to $60.2 million for the same period in 2024[76] - Transformational and restructuring related expenses were $6.6 million for the three months ended March 31, 2025, compared to $8.5 million for the same period in 2024[78] - Total non-operating expenses decreased to $4.0 million for the three months ended March 31, 2025, from $8.1 million for the same period in 2024[81] Cash Flow and Liquidity - Cash used in operating activities decreased to $116.1 million for the three months ended March 31, 2025, from $122.6 million for the same period in 2024[87] - As of March 31, 2025, the company had $99.0 million in cash and cash equivalents, down from $229.9 million at December 31, 2024[85] - The outstanding principal balance on the Amended Credit Agreement was $210.9 million as of March 31, 2025[96] - A 1% change in interest rates would impact income before taxes by approximately $2.1 million per year based on the outstanding balance of the Amended Credit Agreement[104] Operational Metrics - The percentage of patient service revenue reimbursed under government-sponsored healthcare programs decreased during the three months ended March 31, 2025, compared to the same period in 2024[61] - Days sales outstanding (DSO) improved to 47.6 days at March 31, 2025, down from 52.2 days at March 31, 2024[89] Strategic Changes - The company completed the exit of its pediatric office-based practices as of December 31, 2024, to focus on hospital-based and maternal-fetal medicine services[62] - The company anticipates potential impacts from changes in government-sponsored healthcare programs and the expiration of COVID-19 related emergency declarations[67]

• Net revenue of $458 million; • Net income of $21 million; and • Adjusted EBITDA of $49 million. Operating Results– Three Months Ended March 31, 2025 Pediatrix's net revenue for the three months ended March 31, 2025 was $458.4 million, compared to $495.1 million for the prior-year period. This decrease reflects the impact of non-same unit activity, primarily practice dispositions, partially offset by growth in same-unit net revenue of 6.2 percent. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice Pres ...

Core Viewpoint - Pediatrix Medical Group, Inc. is expected to report its first-quarter 2025 results on May 6, 2025, with earnings estimated at 25 cents per share and revenues at $454.5 million, indicating a year-over-year earnings increase of 25% but a revenue decrease of 8.2% [1][2]. Financial Estimates - The Zacks Consensus Estimate for Pediatrix Medical's total revenues for 2025 is $1.9 billion, reflecting a year-over-year decline of 6.6%. The EPS estimate for the current year stands at $1.55, suggesting a growth of 2.7% year-over-year [2]. - The earnings estimate for the first quarter has remained stable over the past 60 days, with the company having beaten consensus earnings estimates in the previous four quarters by an average surprise of 19.4% [2][3]. Earnings Prediction Model - The current model indicates that Pediatrix Medical has an Earnings ESP of 0.00% and a Zacks Rank of 2 (Buy), which does not strongly predict an earnings beat for the upcoming quarter [3]. Revenue Factors - The Zacks Consensus Estimate for first-quarter net patient service revenue indicates a 7.6% year-over-year decline, while hospital contract administrative fees are expected to decline by 10.7% from the previous year, impacting the company's top line [5]. - The same-facility revenue growth is estimated at 0.75%, with patient volume growth at 0% and net reimbursement growth at 0.75%. NICU patient days growth is projected at 1.9% [6]. Operating Expenses - The model estimates a more than 10% year-over-year decline in total operating expenses, attributed to lower practice salaries and benefits, practice supplies, and general administrative costs. The first-quarter interest expense is projected at $8 million, continuing a year-over-year decline [7]. - The adjusted net income for the first quarter is expected to be nearly $21 million, representing a significant increase from the same period last year [7].

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

Figure 1 Midland Announces the Acquisition of the Kan Gold Project Figure 2 Midland Announces the Acquisition of the Kan Gold Project Figure 3 Midland Announces the Acquisition of the Kan Gold Project Figure 4 Midland Announces the Acquisition of the Kan Gold Project Figure 5 Midland Announces the Acquisition of the Kan Gold Project Figure 6 Midland Announces the Acquisition of the Kan Gold Project Figure 7 Midland Announces the Acquisition of the Kan Gold Project Figure 8 <img ...

Core Viewpoint - Midland Exploration Inc. has designated 167 mining claims in the Labrador Trough, Quebec, for its new "Kuiper" project, highlighting strong copper potential based on favorable geological parameters and recent discoveries of high-grade copper mineralization [1][6]. Group 1: Copper Occurrences - During a reconnaissance campaign in 2024, two mineralized boulders with high-grade copper were discovered on the Kuiper project, with grades of 5.26% Cu and 1.75% Cu from a dolomite boulder, and 1.14% Cu from a mafic tuff boulder [3][10]. - Historical high-grade copper showings near the Kuiper project include grades of up to 3.71% Cu over 1.8 meters and 11.4% Cu from grab samples, indicating a favorable geological environment for copper mineralization [4][10]. Group 2: Copper Anomalies - The project contains four of the strongest copper anomalies in lake sediments across Quebec, with one sample grading 0.12% Cu, representing the highest copper grade out of nearly 125,000 lake sediment samples in the province [5][10]. - These unexplained copper anomalies are associated with dolomites and grey-black shales of the Dunphy and Lace Lake formations, further supporting the project's potential [10]. Group 3: Project Development - The designation of 167 mining claims covers areas with strong lake sediment copper anomalies and locations where mineralized boulders were found, totaling 79.7 km [6][10]. - The lake sediment data processing was conducted using statistical methods to correct for natural variations, ensuring the reliability of the copper anomaly data [7][10]. Group 4: Company Overview - Midland Exploration targets the mineral potential of Quebec to discover new world-class deposits of gold and critical metals, collaborating with reputable partners in the industry [13]. - The company is actively reviewing additional opportunities and projects to enhance its portfolio and generate shareholder value [13].

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Core Viewpoint - Pediatrix Medical Group (MD) shows potential for upside with a mean price target of $18.21, indicating a 28% increase from the current trading price of $14.23 [1] Price Target Analysis - The mean estimate consists of seven short-term price targets with a standard deviation of $1.35, suggesting variability in analyst predictions [2] - The lowest estimate of $17 indicates a 19.5% increase, while the highest estimate suggests a 47.6% surge to $21 [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [7] Earnings Estimates - Analysts have shown increasing optimism about MD's earnings prospects, with a strong consensus in revising EPS estimates higher [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 6.1%, with five estimates moving higher and one lower [10] - MD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Analyst Behavior - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated expectations [6] - Despite the skepticism surrounding price targets, the direction implied by them can serve as a useful guide for potential price movements [12]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lose momentum if future growth does not justify high valuations [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, utilizing tools like the Zacks Momentum Style Score to identify potential opportunities [3] Group 2: Pediatrix Medical Group (MD) Analysis - Pediatrix Medical Group (MD) has shown a price increase of 1.4% over the past four weeks, indicating growing investor interest [4] - The stock has gained 4.4% over the past 12 weeks, with a beta of 1.49, suggesting it moves 49% more than the market [5] - MD has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] Group 3: Earnings Estimates and Valuation - An upward trend in earnings estimate revisions has contributed to MD earning a Zacks Rank 1 (Strong Buy), which is associated with strong momentum effects [7] - MD is trading at a Price-to-Sales ratio of 0.61, suggesting it is undervalued as investors pay only 61 cents for each dollar of sales [7] Group 4: Additional Investment Opportunities - Besides MD, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting additional investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies to help identify potential winning stocks based on various investing styles [9]